BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 14, 2011
View Archived Issues
Phase II data suggest fluoxetine improves motor recovery after ischemic stroke
Read More
Merck & Co. patents novel gamma-secretase modulators
Read More
Profectus BioSciences divulges new NF-kappa-B inhibitors
Read More
GSK discovers new lysophospholipid S1P1 receptor agonists
Read More
Vertex Pharma outlines its objectives for 2011
Read More
XL-184 receives FDA orphan drug status and is assigned generic name cabozantinib
Read More
Phase IIb trial evaluates budesonide as chemopreventive therapy in subjects with lung nodules
Read More
Cannabinoid CB1/CB2 receptors show promise as targets in NSCLC
Read More
PET ligand [11C]-RO-5013853 shows promise to evaluate Gly-T1 inhibitors
Read More
FDA accepts NDA for extended-release Janumet for review
Read More
Phase I ViaDerm-Calcitonin trial meets primary and secondary endpoints
Read More
Mithridion secures funding for drug development program
Read More
GSK-1605786 advances in phase III trial in Crohn's disease
Read More
Lilly presents new inhibitors of hedgehog signaling
Read More
FP-1097 is effective in phase II trial in female incontinence and overactive bladder
Read More
FDA accepts SmartRelief-Sumatriptan NDA for filing
Read More
Cephalon and Mesoblast report interim phase II data on Revascor
Read More
New histamine H3 receptor antagonists and/or inverse agonists discovered
Read More
Merck Serono claims new lysophospholipid S1P1 receptor agonists
Read More
FDA advisory committee recommends non-approval of Lilly's liprotamase NDA for EPI
Read More
Pfizer initiates rolling NDA submission for crizotinib for NSCLC
Read More
Enzon begins phase I study of EZN-4176 in castration-resistant prostate cancer
Read More
Daiichi Sankyo and ArQule initiate phase III trial of ARQ-197 in NSCLC
Read More
Shire reports study data on Vyvanse in excessive daytime sleepiness
Read More
